1.57  -0.09 (-5.42%)		10-24 14:05
Open: 1.61 High: 1.6699 Volume: 2,071		Pre. Close: 1.66 Low: 1.57 Market Cap: 16(M)

Short term
Mid term
Targets	6-month :	2.06	1-year :	2.22
Resists	First :	1.76	Second :	1.9
Pivot price	1.65
Supports	First :	1.54	Second :	1.28
MAs	MA(5) :	1.63	MA(20) :	1.68
	MA(100) :	1.62	MA(250) :	1.94
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	30.6	D(3) :	36.7
RSI	RSI(14): 38.6
52-week	High :	3.89	Low :	1.1

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ANL ] has closed above bottom band by 9.4%. Bollinger Bands are 19.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.66 - 1.67	1.67 - 1.67
Low:	1.53 - 1.54	1.54 - 1.55
Close:	1.65 - 1.66	1.66 - 1.67

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.

Tue, 03 Oct 2023
Adlai Nortye Ltd. Announces Closing of Initial Public Offering - GlobeNewswire

Fri, 29 Sep 2023
Adlai Nortye Ltd. has completed an IPO in the amount of $57.5 million. - MarketScreener

Fri, 29 Sep 2023
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering - GlobeNewswire

Fri, 24 Oct 2025

Fri, 24 Oct 2025

Fri, 24 Oct 2025

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	31 (M)
Held by Insiders	6.671e+007 (%)
Held by Institutions	8.5 (%)
Shares Short	3 (K)
Shares Short P.Month	0 (K)

EPS	-5.192e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-1 %
Return on Assets (ttm)	220.8 %
Return on Equity (ttm)	-32.9 %
Qtrly Rev. Growth	1.94e+006 %
Gross Profit (p.s.)	0
Sales Per Share	0.13
EBITDA (p.s.)	-1.8
Qtrly Earnings Growth	-1.7 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-52 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	11.58
Price to Cash Flow	-2.01

Dividend	0
Forward Dividend	2450
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.